CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
Lp(a) ≥ 150 nmol/L
Clinical syndrome consistent with spontaneous cardiac ischemia
Diagnosis of ACS: ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)
Uncontrolled hypertension
Heart failure New York Heart Association (NYHA) class IV
History of malignancy of any organs
History of hemorrhagic stroke or other major bleeding